Front. Mol. Biosci. Frontiers in Molecular Biosciences Front. Mol. Biosci. 2296-889X Frontiers Media S.A. 750558 10.3389/fmolb.2021.750558 Molecular Biosciences Original Research Respiratory Outcomes in Patients Following COVID-19-Related Hospitalization: A Meta-Analysis Guo et al. Post-COVID Respiratory Outcomes Guo Tao 1 Jiang Fangfang 2 Liu Yufei 3 Zhao Yunpeng 4 Li Yiran 5 Wang Yihua 1 * Biological Sciences, Faculty of Environmental and Life Sciences, University of Southampton, Southampton, United Kingdom Department of Mathematical Sciences, Faculty of Social Sciences, University of Southampton, Southampton, United Kingdom School of Food Science and Technology, Jiangnan University, Wuxi, China School of Medicine and Integrated Medicine, Nanjing University of Chinese Medicine, Nanjing, China School of Artificial Intelligence and Information Technology, Nanjing University of Chinese Medicine, Nanjing, China

Edited by: Rana Jahanban-Esfahlan, Tabriz University of Medical Sciences, Iran

Reviewed by: Doaa El Amrousy, Faculty of Medicine, Tanta University, Egypt

Effat Alizadeh, Tabriz University of Medical Sciences, Iran

Giovanni Barisione, IRCCS Ospedale Policlinico San Martino, Italy

 *Correspondence: Yihua Wang, yihua.wang@soton.ac.uk

This article was submitted to Molecular Diagnostics and Therapeutics, a section of the journal Frontiers in Molecular Biosciences

 06 10 2021 2021 8 750558 30 07 2021 07 09 2021 Copyright © 2021 Guo, Jiang, Liu, Zhao, Li and Wang. 2021 Guo, Jiang, Liu, Zhao, Li and Wang

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Background: To determine the respiratory outcomes in patients following COVID-19-related hospitalization.

Methods: Systematic review and meta-analysis of the literature.

Results: Forced vital capacity (FVC, % of predicted): 0–3 months post discharge: 96.1, 95% CI [82.1–110.0]; 3–6 months post discharge: 99.9, 95% CI [84.8, 115.0]; >6 months post discharge: 97.4, 95% CI [76.8–118.0]. Diffusing capacity of the lungs for carbon monoxide (DLCO, % of predicted): 0–3 months post discharge: 83.9, 95% CI [68.9–98.9]; 3–6 months post discharge: 91.2, 95% CI [74.8–107.7]; >6 months post discharge: 97.3, 95% CI [76.7–117.9]. Percentage of patients with FVC less than 80% of predicted: 0–3 months post discharge: 10%, 95% CI [6–14%]; 3–6 months post discharge: 10%, 95% CI [2–18%]; >6 months post discharge: 13%, 95% CI [8–18%]. Percentage of patients with DLCO less than 80% of predicted: 0–3 months post discharge: 48%, 95% CI [41–56%]; 3–6 months post discharge: 33%, 95% CI [23–44%]; >6 months post discharge: 43%, 95% CI [22–65%].

Conclusion: The meta-analysis confirms a high prevalence of persistent lung diffusion impairment in patients following COVID-19-related hospitalization. Routine respiratory follow-up is thus strongly recommended.

 COVID-19 follow-up pulmonary function test FVC DLCO synthesis review meta-analysis National Health and Medical Research Council10.13039/501100000925 Introduction

To date, over 200 million people worldwide have recovered from COVID-19 (https://www.worldometers.info/coronavirus/) (Worldometers (2020). Worl, 2020), but concern remains that some organs, including the lungs, might suffer long-term impairment following recovery from acute infections. Individual studies have shown that residual abnormalities of pulmonary function were observed in a subgroup of recovered COVID-19 patients, with the most common finding being a reduction in gas transfer as measured by diffusing capacity of the lungs for carbon monoxide (DLCO) (Hull et al., 2020; Dhawan et al., 2021; Thomas et al., 2021). In this study, with meta-analysis, we aimed to determine the short (0–3 months), medium (3–6 months) and long (>6 months) respiratory outcomes in patients following COVID-19-related hospitalisation. The findings will instruct appropriate interventions for subsequent increased healthcare utilisation post-COVID-19.

 Method Criteria for Inclusion

We included randomised controlled trials (RCTs) and observational studies (cross-sectional, longitudinal, case-control and cohort) of patients with a confirmed diagnosis of COVID-19. The studies included aimed to determine the respiratory outcomes, in particular forced vital capacity (FVC) and diffusing capacity of the lungs for carbon monoxide (DLCO), in patients following COVID-19-related hospitalisation. The selected studies had to follow the ATS / ERS clinical guidelines. The included literatures should be published before May 15, 2021.

 Criteria for Exclusion

Study’s subjects who were not infected with COVID-19. Studies didn’t report the time of hospital discharge or the time was calculated from diagnosis of COVID-19. Studies did not report FVC (% of predicted) or DLCO (% of predicted) or FVC <80% of predicted or DLCO <80% of predicted. Animal experiments, medical records, case reports, famous medical experience and review were excluded.

 Literature Retrieval and Selection

Firstly, according to the literature inclusion criteria, two researchers independently searched at Pubmed, ScienceDirect, Embase and Web of Science. Secondly, two researchers selected the literature and extracted the data independently in accordance with the standard data extraction table. When it came to divergences, a third researcher did the judgement. After the discussion, researchers reached a consensus. Finally, after the extraction and input of the data, two independent researchers did the subsequent analysis.

 Extraction of Data

According to the inclusion criteria, we assessed the design of research, patients, and outcome indicators. First author, published year, number of cases, nationality, ages, body mass index (BMI), smoking status, respiratory comorbidities, time of assessment and, index quantity of FVC, % of predicted, DLCO, % of predicted; FVC <80% of predicted and DLCO <80% of predicted were extracted from eligible studies.

 Quality Assessment of Articles

The studies with randomised controlled trials were evaluated by Newcastle-Ottawa Scale (Bellan et al., 2021). As for no controlled trials, it includes the following aspects: 1) selection: Representativeness of the exposed cohort, selection of the non-exposed cohort, Ascertainment of exposure, Demonstration that outcome of interest was not present at start of study; 2) comparability: Research control matched important factors, but also controlled other important factors; and 3) outcome: assessment of outcome, follow-up long enough for outcomes to occur, adequacy of follow up of cohorts.

 Synthesis and Analysis of Data

We used package “meta (version 4.18-0)” in R 4.0.1 and R studio to perform meta-analysis of the following pulmonary function tests (PFTs) indexes (1. FVC, % of predicted; 2. DLCO, % of predicted; 3. FVC <80% of predicted; 4. DLCO <80% of predicted.). Patients were divided into three groups: less than 3 months (0–3 months), more than or equal to 3 months and less than 6 months (3–6 months), and more than or equal to 6 months (≥6 months). We re-calculated the median (first quantile, third quantile) to mean ± standard deviation (SD) for FVC (% of predicted) and DLCO (% of predicted) in several studies. Statistical heterogeneity was measured through the I2 statistic and classified as low (I2 < 25%), moderate (I2 25–50%), and high (I2 > 50%) (Melsen et al., 2014). Subgroup analysis, according to the outcome assessment and severity, was performed. Sensitivity analysis was also employed to assess the change in pooled prevalence due to the selective exclusion of studies.

 Results Literature Extraction

A total of 1,123 articles was retrieved from databases via the retrieval methods. Duplicate literatures were excluded through titles and abstracts. By reading the full text, we excluded 1,110 papers and conference abstracts with incomplete or no specific research method. Finally, 13 papers published in English were included (Liang et al., 2020; Huang et al., 2020; Venturelli et al., 2021; You et al., 2020; Lerum et al., 2021; Daher et al., 2020; Wu et al., 2021; Bellan et al., 2021; Li et al., 2020; van den Borst et al., 2020; Mo et al., 2020; Zhao et al., 2020; Huang et al., 2021), with a total of 3,455 patients. The evaluation of the quality of included studies by Newcastle-Ottawa Scale (NOS) (Stang et al., 2018) showed that two studies had a poor quality and the rest 11 studies passed the quality control. The basic characteristics of the included literatures were detailed in Table 1 and the procedure of literature retrieval and selection was shown in Figure 1.

Basic characteristics of included studies.

Author Country Design Participants male/female Age (years) BMI (kg/m2) Smoking Respiratory comorbidities Time of assessment Quality rating
Huang et al., (2020) China retrospective 57 26M/31F 46.7 ± 13.7 23.9 ± 3.5 History of smoking 9 (15.7%) No patient was reported having chronic repiratory diseases 30 days after discharge from the hospital high
Venturelli et al., (2021) Italy prospective 767 515M/252F 63 ± 13.6 NR Active smoker 33 (4.3%) History of smoking 179 (23.3%) NR 81 (66–106) days after hospital discharge high
You et al., (2020) China prospective 18 10M/8F 50.7 ± 12.1 26.4 ± 2.8 NR No patient was reported having chronic repiratory diseases 38 ± 13.4 days after hospital discharge high
Lerum et al., (2021) Norway prospective 103 54M/49F 59 (49–72) 25.8 (23.8–29.6) Current smoker 3 (3.4%) previous smoker 34 (39%) NR 3 months after hospital admission poor
Daher et al., (2020) Germany prospective 33 22M/11F 64 ± 3 28 (24–31) NR 7 (21%) 6 weeks after hospital discharge high
Wu et al., (2021) China prospective, longitudinal, cohort  83 47M/36F 60 (52–66) 25 (23.5–27.1) NR No patient was reported having chronic repiratory diseases 3 months, 6 months, 9 months, 12 months after hospital discharge high
Liang et al., (2020) China Prospective 76 21M/55F 41.3 ± 13.8 23.7 ± 4.5 NR Cough 45 (60%) Increased sputum production 33 (43%) Activity chest tightness and palpitations 47 (62%) 3 -months follow-up study after discharge high
Bellan et al., (2021) Italy prospective cohort study 238 142M/96F 61 (51–71) NR Never 139(58.4%)Former 74(31.1%)Current 25(10.5%)Pack-years,median(IQR) 15(7.25–36) No patient was reported having chronic repiratory diseases 4 months after discharge high
Li et al., (2020) China a prospective study 18 NR NR History of smoking 3(16.6%) history of tuberculosis 1 (5.5%) Near discharge and in quarantine period (2 weeks after discharge) high
van den Borst et al., (2020) Netherlands Prospective 124 74M/50F 59 ± 14 NR Never 48(39%)Former 74(60%)Current 2(2%) asthma 12 (10%) chronic lung diseases 23 (19%) other lung diseases 4 (3%) Three months after recovery high
Mo et al., (2020) China Prospective 110 55M/55F 49.1 ± 14.0 23.5 ± 3.0 History of smoking 13 (11.8%) asthma 1 (0.9%) chronic bronchitis 1 (0.9%) bronchiectasis 1 (0.9%) At time of hospital discharge poor
Zhao et al., (2020) China retrospective 55 22M/23F 47.7 ± 15.5 NR active 2 (3.6%) former 2 (3.6%) cough 7 (43.75%) 3 months after hospital discharge high
Huang et al., (2021) China prospective cohort study 1733 897M/836F 57 (47–65) NR Never-smoker 1585/1731 (92%) Current smoker 102/1731 (6%) Former smoker 44/1731 (3%) Chronic obstructive pulmonary disorder 31 (2%) 153.0 (146.0–160.0) days after hospital discharge high

NR, not reported; BMI, body mass index; M, male; F, female.

Workflow showing literature extraction (details provided in Methods).

Among the included studies, 10 studies reported FVC (% of predicted), eight studies reported DLCO (% of predicted), six reported FVC <80% of predicted, and nine reported DLCO <80% of predicted. Wu et al. (2021) . reported all the indexes of the patients after the 3, 6 and 12 months following COVID-19-related hospitalisation (Table 2). For those data reported in the form of median (first quantile, third quantile), we used R studio to re-calculate them into mean ± SD (Table 3).

Summary of studies included pulmonary function test.

Wu et al., (n = 83) You et al., (n = 18) Zhao et al., (n = 55)
FVC, % of predicted 92 (81–99) 94 (85–104) 98 (89–109) 105.1 ± 23.3 NR
DLCO, % of predicted 77 (67–87) 76 (68–90) 88 (78–101) NR NR
FVC, < 80% of predicted 19 13 9 3 NR
DLCO, < 80% of predicted 46 45 27 NR 9
Time of assessment 3 months 6 months 12 months 38 ± 13.4 days after hospital discharge 3 months after hospital discharge
Lerum et al., (n = 103) Borst et al., (n = 124) Li et al., (n = 18) Daher, A et al. (n = 33) Venturelli, S et al. (n = 767)
FVC, % of predicted 94 (76–121) NR 91.5 ± 17.3 NR 95(84–106), f
DLCO, % of predicted 83 (72–92) 81 ± 17 NR 65(53–73) 96(81–112), p
FVC, < 80% of predicted 7 NR NR NR NR
DLCO, < 80% of predicted 24 41 NR NR NR
Time of assessment 3 months after hospital discharge 3 months after recovery Near to discharge and 2 weeks after 56 days from discharge to follow-up 80(median)days after discharge
Huang et al. (n = 349) Bellan et al., (n = 224) Liang et al., (n = 76) Huang et al., (n = 57) Mo et al., (n = 110)
FVC, % of predicted NR 98.5 (90–109) 107.1 ± 12.3 100.96 ± 15.93 93.59 ± 12.25
DLCO, % of predicted NR 79 (69–89), q NR 78.38 ± 13.59 78.18 ± 14.29
FVC, < 80% of predicted 14 NR NR 6 10
DLCO, < 80% of predicted 114, I 113, q 15 30 51
Time of assessment 153.0 (146.0–160.0) days after hospital discharge 4 months after hospital discharge 3 months after hospital discharge 1 month after hospital discharge when discharged from hospital

f: n = 717, p: n = 680, q: n = 219, l: n = 334.

NR, not reported; FVC, forced vital capacity; DLCO, diffusing capacity for carbon monoxide.

Summary of re-calculations of median into mean using R studio.

Author Time FVC.mean FVC.sd FVC.n DLCO.mean DLCO.sd DLCO.n
Frija-Masson 30 days after symptoms onset 91.7 11.14 50 91.27 11.23 50
Daher, A 56 days from discharge to follow-up NR NR NR 88.93 17.67 33
Venturelli, S 80(median)days after discharge 95.02 15.99 717 95.48 16.6 680
Lerum 3 months after hospital discharge 102.1 37.78 103 99.68 34.9 103
Darley,D.R 113(median)days after diagnosis 106.91 15.07 65 106.88 14.79 65
Belan 4 months after hospital discharge 99.9 14.3 224 99.79 14.28 219
Wu 3 months 89.11 14.73 83 88.45 14.13 83
Wu 6 months 95.07 14.3 83 95.26 14.26 83
Wu 12 months 100.19 15.53 83 99.67 15.56 83

FVC, forced vital capacity; DLCO, diffusing capacity for carbon monoxide; NR, Not reported.

Publication bias refers to the fact that research results with statistical significance are more likely to be reported and published than those without statistical significance and invalid results (DeVito and Goldacre, 2019). We examined the publication bias of meta-analysis of each indicator. There was no publication bias in FVC (% of predicted; p = 0.93; Figure 2A), DLCO (% of predicted; p = 0.54; Figure 2B) and DLCO (<80% of predicted; p = 0.94; Figure 2C). For FVC <80% of predicted, less than 10 studies were included, so publication bias was not tested.

No publication bias of the meta-analysis. Funnel plots of FVC (% of predicted) (A), DLCO (% of predicted) (B) and DLCO <80% of predicted (C) were shown. Each dot represents a study.

 Comparison of Longitudinal Changes in FVC (% of Predicted)

Nine studies with 11 groups of data showed the results of FVC (% of predicted). Based on the time of patients discharged from hospital, we divided them into three groups: 0–3 months, 3–6 months and ≥6 months. FVC (% of predicted) in 0–3 months, 3–6 months and ≥6 months post discharge were 96.1 (95% CI [82.1–110.0]), 99.9 (95% CI [84.8–115.0]) and 97.4 (95% CI [76.8–118.0]), respectively. In this study, heterogeneity was extremely low (I2 = 0%), and the overall value of FVC (% of predicted) in all studies was 97.7 (95% CI [88.6–106.9]) (Figure 3).

Comparison of longitudinal changes in FVC (% of predicted). Forest plot showing meta-analysis of FVC (% of predicted).

 Comparison of Longitudinal Changes in DLCO (% of Predicted)

Eight studies with 10 groups of data showed the results of DLCO (% of predicted). DLCO (% of predicted) in 0–3 months, 3–6 months and ≥6 months post discharge were 83.9 (95% CI [68.9–98.9]), 91.2 (95% CI [74.8–107.7]) and 97.3 (95% CI [76.7–117.9]), respectively. Heterogeneity was considered low (I2 = 0%) using a fixed effect model (Melsen et al., 2014; Bellou et al., 2016) (Figure 4).

Comparison of longitudinal changes in DLCO (% of predicted). Forest plot showing meta-analysis of DLCO (% of predicted).

Comparison of longitudinal changes in the percentage of patients with FVC <80% of predicted.

These included six studies, which in total have eight groups of data showed the percentage of patients with FVC less than 80% of predicted. Based on the time of patients being discharged from hospital, we divided them into three groups: 0–3 months, 3–6 months and greater than 6 months. Meta-analysis showed that the percentage of patients with FVC less than 80% of predicted in 0–3 months, 3–6 months and ≥6 months post discharge was 10% (95% CI [6–14%]), 10% (95% CI [2–18%]) and 13% (95% CI [8–18%], respectively. The heterogeneity of 3–6 months was large, so the sensitivity analysis was carried out in this study. We removed the study from Wu et al. and got the meta-analysis result of this subgroup, which was 4% (95% CI [3–6%]) with I2 = 6% (Figure 5).

Comparison of longitudinal changes in the percentage of patients with FVC <80% of predicted. Forest plot showing meta-analysis of the percentage of patients with FVC <80% of predicted.

Comparison of longitudinal changes in the percentage of patients with DLCO <80% of predicted.

This included nine studies, which have 11 groups of data shows the results of DLCO less than 80% of predicted. Meta-analysis showed a significant and persistent reduction in DLCO over the study period. The percentage of patients with DLCO less than 80% of predicted in 0–3 months, 3–6 months and ≥6 months post discharge was 48% (95% CI [41–56%]), 33% (95% CI [23–44%]) and 43% (95% CI [22–65%]), respectively (Figure 6).

Comparison of longitudinal changes in the percentage of patients with DLCO <80% of predicted. Forest plot showing meta-analysis of the percentage of patients with DLCO <80% of predicted.

 Discussion

Post-acute COVID-19 syndrome, also known as long COVID, encompasses a wide range of physical and mental health symptoms that persist after recovery from acute SARS-CoV-2 infections (Nalbandian et al., 2021). Systematic studies of sequelae after recovery from acute COVID-19 are demanded to inform effective clinical management for patients suffered from long COVID.

We recently reported the 3 months, 6 months, 9 months, and 12 months respiratory outcomes in patients following COVID-19-related hospitalisation from a relatively small prospective cohort (n = 83) (Wu et al., 2021). In this study, we conducted meta-analysis to determine the short (0–3 months), medium (3–6 months) and long (>6 months) respiratory outcomes in patients following COVID-19-related hospitalisation. Significantly, we found a persistent reduction in DLCO over the study period, consistent with earlier reports (E et al., 2021). Low DLCO could be caused by interstitial changes or pulmonary vascular abnormalities following COVID-19 infections (Lang et al., 2020; Patel et al., 2020; Hanidziar and Robson, 2021). Our study has shown that up to a third of COVID patients still have evidence of defect DLCO 1 year after discharge (Wu et al., 2021), although longer term follow-up with a larger cohort will be required to confirm this observation.

In general, the heterogeneity of the studies included in the meta-analysis was low. However, the heterogeneity of DLCO less than 80% of predicted was higher, which may be caused by different ethnic groups, ages, disease severity, therapies and other factors. In general, the models we used were robust and reliable.

There are several limitations in this study. Firstly, age, sex ratio, nationality and disease severity of the patients included in the study are quite different, which may cause great heterogeneity and affect the final research results. Secondly, we only selected four indicators of lung function, so we cannot investigate the relationship between other indicators and discharge time. To be consistent and comparable with our earlier publication (Wu et al., 2021), we excluded those studies without data on FVC and/or DLCO values <80% of predicted. This might cause some false positive results considering the mean age of included patients is over 50 (van den Borst et al., 2020; Barisione and Brusasco, 2021; Milanese et al., 2021). In addition, pre-existing comorbidities for most COVID-19 patients are not known, which might cause certain bias of the results. Despite of these limitations, our findings in this meta-analysis are consistent with our previous report (Wu et al., 2021), confirming a high prevalence of persistent lung diffusion impairment in patients following COVID-19-related hospitalisation. Routine respiratory follow-up is thus strongly recommended.

 Data Availability Statement

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author.

 Author Contributions

YW conceived and designed the study. TG, FJ, YL, YZ and YL collected the data. TG and FJ performed the data analysis. TG and YL did the evaluation of the quality of included articles. TG and YW wrote the article. All authors are responsible for reviewing data. All authors read and approved the final article.

 Funding

YW was supported by Medical Research Council (United Kingdom) (MR/S025480/1).

 Conflict of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

 Publisher’s Note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors, and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

 Abbreviations

BMI, body mass index; COVID-19, Corona virus disease 2019; DLCO, diffusing capacity for carbon monoxide; FVC, forced vital capacity; NR, not reported; PFTs, pulmonary function tests.

 References Barisione G. Brusasco V. (2021). Lung diffusing capacity for nitric oxide and carbon monoxide following mild-to-severe COVID-19. Physiol. Rep. 9 (4), e14748. 10.14814/phy2.14748 Bellan M. Soddu D. Balbo P. E. Baricich A. Zeppegno P. Avanzi G. C. (2021). Respiratory and Psychophysical Sequelae Among Patients With COVID-19 Four Months after Hospital Discharge. JAMA Netw. Open 4 (1), e2036142. 10.1001/jamanetworkopen.2020.36142 Bellou V. Belbasis L. Tzoulaki I. Evangelou E. Ioannidis J. P. A. (2016). Environmental risk factors and Parkinson's disease: An umbrella review of meta-analyses. Parkinsonism Relat. Disord. 23, 1–9. 10.1016/j.parkreldis.2015.12.008 Daher A. Balfanz P. Cornelissen C. Müller A. Bergs I. Marx N. (2020). Follow up of patients with severe coronavirus disease 2019 (COVID-19): Pulmonary and extrapulmonary disease sequelae. Respir. Med. 174, 106197. 10.1016/j.rmed.2020.106197 DeVito N. J. Goldacre B. (2019). Catalogue of bias: publication bias. Bmj Ebm 24 (2), 53–54. 10.1136/bmjebm-2018-111107 Dhawan R. T. Gopalan D. Howard L. Vicente A. Park M. Manalan K. (2021). Beyond the clot: perfusion imaging of the pulmonary vasculature after COVID-19. Lancet Respir. Med. 9 (1), 107–116. 10.1016/s2213-2600(20)30407-0 Ekbom E. Frithiof R. Emilsson Öi. Larson I.M. Lipcsey M. Rubertsson S. (2021). Impaired diffusing capacity for carbon monoxide is common in critically ill Covid-19 patients at four months post-discharge. Respir. Med. 182, 106394. 10.1016/j.rmed.2021.106394 Hanidziar D. Robson S. C. (2021). Hyperoxia and modulation of pulmonary vascular and immune responses in COVID-19. Am. J. Physiology-Lung Cell Mol. Physiol. 320 (1), L12–L16. 10.1152/ajplung.00304.2020 Huang C. Huang L. Wang Y. Li X. Ren L. Gu X. (2021). 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. The Lancet 397 (10270), 220–232. 10.1016/s0140-6736(20)32656-8 Huang Y. Tan C. Wu J. Chen M. Wang Z. Luo L. (2020). Impact of coronavirus disease 2019 on pulmonary function in early convalescence phase. Respir. Res. 21 (1), 163. 10.1186/s12931-020-01429-6 Hull J. H. Lloyd J. K. Cooper B. G. (2020). Lung function testing in the COVID-19 endemic. Lancet Respir. Med. 8 (7), 666–667. 10.1016/s2213-2600(20)30246-0 Lang M. Som A. Mendoza D. P. Flores E. J. Reid N. Carey D. (2020). Hypoxaemia related to COVID-19: vascular and perfusion abnormalities on dual-energy CT. Lancet Infect. Dis. 20 (12), 1365–1366. 10.1016/s1473-3099(20)30367-4 Lerum T. V. Aaløkken T. M. Brønstad E. Aarli B. Ikdahl E. Lund K. M. A. (2021). Dyspnoea, lung function and CT findings 3 months after hospital admission for COVID-19. Eur. Respir. J. 57 (4), 2003448. 10.1183/13993003.03448-2020 Li X. Wang C. Kou S. Luo P. Zhao M. Yu K. (2020). Lung ventilation function characteristics of survivors from severe COVID-19: a prospective study. Crit. Care 24 (1), 300. 10.1186/s13054-020-02992-6 Liang L. Yang B. Jiang N. Fu W. He X. Zhou Y. (2020). Three-month Follow-up Study of Survivors of Coronavirus Disease 2019 after Discharge. J. Korean Med. Sci. 35 (47), e418. 10.3346/jkms.2020.35.e418 Melsen W. G. Bootsma M. C. J. Rovers M. M. Bonten M. J. M. (2014). The effects of clinical and statistical heterogeneity on the predictive values of results from meta-analyses. Clin. Microbiol. Infect. 20 (2), 123–129. 10.1111/1469-0691.12494 Milanese M. Anselmo M. Buscaglia S. Garra L. Goretti R. Parodi L. (2021). COVID-19 6 months after hospital discharge: pulmonary function impairment and its heterogeneity. ERJ Open Res. 7 (3), 00196–02021. 10.1183/23120541.00196-2021 Mo X. Jian W. Su Z. Chen M. Peng H. Peng P. (2020). Abnormal pulmonary function in COVID-19 patients at time of hospital discharge. Eur. Respir. J. 55 (6), 2001217. 10.1183/13993003.01217-2020 Nalbandian A. Sehgal K. Gupta A. Madhavan M. V. McGroder C. Stevens J. S. (2021). Post-acute COVID-19 syndrome. Nat. Med. 27 (4), 601–615. 10.1038/s41591-021-01283-z Patel B. V. Arachchillage D. J. Ridge C. A. Bianchi P. Doyle J. F. Garfield B. (2020). Pulmonary Angiopathy in Severe COVID-19: Physiologic, Imaging, and Hematologic Observations. Am. J. Respir. Crit. Care Med. 202 (5), 690–699. 10.1164/rccm.202004-1412oc Stang A. Jonas S. Poole C. (2018). Case study in major quotation errors: a critical commentary on the Newcastle-Ottawa scale. Eur. J. Epidemiol. 33 (11), 1025–1031. 10.1007/s10654-018-0443-3 Thomas M. Price O. J. Hull J. H. (2021). Pulmonary function and COVID-19. Curr. Opin. Physiol. 21, 29–35. 10.1016/j.cophys.2021.03.005 van den Borst B. Peters J. B. Brink M. (2020). Comprehensive health assessment three months after recovery from acute COVID-19. Clin. Infect. Dis. 10.1093/cid/ciaa1750 Venturelli S. Benatti S. V. Casati M. Binda F. Zuglian G. Imeri G. (2021). Surviving COVID-19 in Bergamo province: a post-acute outpatient re-evaluation. Epidemiol. Infect. 149, e32. 10.1017/s0950268821000145 Worldometers (2020). World Meter Corona Virus Update. (Live) Available from https://www.worldometers.info/coronavirus/. Wu X. Liu X. Zhou Y. Yu H. Li R. Zhan Q. (2021). 3-month, 6-month, 9-month, and 12-month respiratory outcomes in patients following COVID-19-related hospitalisation: a prospective study. Lancet Respir. Med. 9 (7), 747–754. 10.1016/S2213-2600(21)00174-0 You J. Zhang L. Ni-Jia-Ti M.-y. -d. -l. Zhang J. Hu F. Chen L. (2020). Anormal pulmonary function and residual CT abnormalities in rehabilitating COVID-19 patients after discharge. J. Infect. 81 (2), e150–e152. 10.1016/j.jinf.2020.06.003 Zhao Y.-m. Shang Y.-m. Song W.-b. Li Q.-q. Xie H. Xu Q.-f. (2020). Follow-up study of the pulmonary function and related physiological characteristics of COVID-19 survivors three months after recovery. EClinicalMedicine 25, 100463. 10.1016/j.eclinm.2020.100463